tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2013 Jan 2. [Epub ahead of print]
Targeting the "Cytokine Storm" for therapeutic benefit.
D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC.
Source
Biomedical Sciences, Dstl Porton Down, Salisbury, SP4 0JQ, UK.
Abstract
Inflammation is the body's first line of defence against infection or injury, responding to challenges by activating innate and adaptive responses. Microbes have evolved a diverse range of strategies to avoid triggering inflammatory responses. However, some pathogens such as the Influenza virus and the Gram negative bacterium Francisella tularensis, do trigger life-threatening cytokine storms in the host which can result in significant pathology and ultimately death. For these diseases, it has been proposed that down-regulating inflammatory immune responses may improve outcome. We review some of the current candidates for treatment of cytokine storms which may prove useful in the clinic in the future, and compare them to more traditional therapeutic candidates that target the pathogen rather than the host response.
PMID:
23283640
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23283640
Targeting the "Cytokine Storm" for therapeutic benefit.
D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC.
Source
Biomedical Sciences, Dstl Porton Down, Salisbury, SP4 0JQ, UK.
Abstract
Inflammation is the body's first line of defence against infection or injury, responding to challenges by activating innate and adaptive responses. Microbes have evolved a diverse range of strategies to avoid triggering inflammatory responses. However, some pathogens such as the Influenza virus and the Gram negative bacterium Francisella tularensis, do trigger life-threatening cytokine storms in the host which can result in significant pathology and ultimately death. For these diseases, it has been proposed that down-regulating inflammatory immune responses may improve outcome. We review some of the current candidates for treatment of cytokine storms which may prove useful in the clinic in the future, and compare them to more traditional therapeutic candidates that target the pathogen rather than the host response.
PMID:
23283640
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23283640